Spain
INBRAIN Neuroelectronics, founded in 2020, is at the forefront of developing high-density and high-resolution graphene neural systems aimed at both central and peripheral neuroelectronic applications. The company, based in Spain, is pioneering a new era in precision neurology with its innovative approach.
Notably, INBRAIN has secured the prestigious FDA Breakthrough Designation, underscoring the disruptive potential of their technology in the industry. Operating within a spectrum of sectors, including AI, Biotechnology, Consumer Electronics, Health Care, Health and Wellness, Medical Devices, and Semiconductors, the company is strategically positioned to influence multiple market segments.
Their latest financial milestone, a €4.00M Grant investment, was received on 01 May 2025 from Turismo Capital. This investment marks a critical enhancement of their funding, providing the resources necessary to further develop and commercialize their advanced neural systems. INBRAIN is a promising target for investors interested in transformative innovations in medical technology.
